Form 4: Anika Therapeutics Director Glenn R. Larsen Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Glenn R. Larsen reports acquisition of 5,771 restricted stock units in Anika Therapeutics, Inc.
Summary
- On July 9, 2024, Glenn R. Larsen, a director of Anika Therapeutics, Inc., acquired 5,771 restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of Anika Therapeutics' common stock.
- The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025.
- Following the transaction, Larsen beneficially owns 36,094 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It reflects routine transactions related to executive compensation.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology and pharmaceutical industries.
Stakeholder Impact
- The acquisition of restricted stock units by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/09/2024 | Date of transaction: Acquisition of 5,771 restricted stock units. |
| 07/09/2025 | RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. |
| 07/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.